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Abstract
Background: Lymphatic metastasis, facilitated by lymphangiogenesis is a common occurrence in breast cancer,
the molecular mechanisms remaining incompletely understood. We had earlier shown that cyclooxygenase (COX)-2
expression by human or murine breast cancer cells promoted lymphangiogenesis and lymphatic metastasis by
upregulating VEGF-C/D production by tumor cells or tumor-associated macrophages primarily due to activation
of the prostaglandin receptor EP4 by endogenous PGE2. It is not clear whether tumor or host-derived PGE2 has
any direct effect on lymphangiogenesis, and if so, whether EP4 receptors on lymphatic endothelial cells (LEC) play
any role.
Methods: Here, we address these questions employing in vitro studies with a COX-2-expressing and VEGF-C/D-
producing murine breast cancer cell line C3L5 and a rat mesenteric (RM) LEC line and in vivo studies in nude mice.
Results: RMLEC responded to PGE2, an EP4 agonist PGE1OH, or C3L5 cell-conditioned media (C3L5-CM) by
increased proliferation, migration and accelerated tube formation on growth factor reduced Matrigel. Native tube
formation by RMLEC on Matrigel was abrogated in the presence of a selective COX-2 inhibitor or an EP4 antagonist.
Addition of PGE2 or EP4 agonist, or C3L5-CM individually in the presence of COX-2 inhibitor, or EP4 antagonist,
restored tube formation, reinforcing the role of EP4 on RMLEC in tubulogenesis. These results were partially duplicated
with a human dermal LEC (HMVEC-dLyAd) and a COX-2 expressing human breast cancer cell line MDA-MB-231.
Knocking down EP4 with shRNA in RMLEC abrogated their tube forming capacity on Matrigel in the absence or
presence of PGE2, EP4 agonist, or C3L5-CM. RMLEC tubulogenesis following EP4 activation by agonist treatment
was dependent on PI3K/Akt and Erk signaling pathways and VEGFR-3 stimulation. Finally in a directed in vivo
lymphangiogenesis assay (DIVLA) we demonstrated the lymphangiogenic as well as angiogenic capacity of PGE2
and EP4 agonist in vivo.
Discussion/conclusions: These results demonstrate the roles of tumor as well as host-derived PGE2 in inducing
lymphangiogenesis, at least in part, by activating EP4 and VEGFR-3 on LEC. EP4 being a common target on both
tumor and host cells contributing to tumor-associated lymphangiogenesis reaffirms the therapeutic value of EP4
antagonists in the intervention of lymphatic metastasis in breast cancer.
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Background
Lymphatic metastasis is a frequent occurrence in most epi-
thelial cancers [1], including cancers of the breast [2],
stomach [3], colon [4], pharynx and larynx [5], lungs [6],
uterine cervix [7], prostate [8] and the ovary [9], negatively
impacting patient survival. This is also the first route of
spread for many cancers, which can subsequently
metastasize from the lymph nodes to other organs via the
blood stream. A positive association between intra-tumoral
and /or peri-tumoral lymphangiogenesis with lymphatic
metastasis noted in many cancers e.g., cancers of the phar-
ynx and larynx [5] and the breast [10, 11], suggests that
newly formed lymphatics serve as conduits for entry and
spread of cancer cells to lymph nodes. Development of
new lymphatic capillaries (lymphangiogenesis) is an event
common to inflammation and carcinogenesis suggesting a
commonality of molecular players in both events. Numer-
ous ligands such as VEGF-C, VEGF–D, neuropilins, and
certain chemokines have been shown to exert a direct
growth-stimulatory effect on cancer-associated lymphatic
endothelial cells (LEC) by activation of their respective re-
ceptors [12–15]. However, the roles of prostaglandin (PG)
E2, another key inflammation-associated molecule, remain
to be explored fully in breast cancer-associated lymphatic
outgrowth.
Expression of cyclooxygenase (COX)-2, an inflammation-
associated enzyme stimulates progression and metastasis
of a variety of cancers including breast cancer [16–18].
COX-2 promotes lymphatic metastasis of postpartum
breast cancer [19]. PGE2 in the tumor micro-environment
resulting from elevated COX-2 expression by cancer or
host cells promotes breast cancer progression by multiple
mechanisms: inactivation of host anti-tumor immune cells
[20, 21], stimulation of tumor cell migration [22, 23], inva-
siveness [23, 24], induction of stem-like cells (SLC) [25],
tumor-associated angiogenesis [22] and lymphangiogen-
esis [26]. The latter results from an upregulation of lym-
phangiogenic growth factors VEGF-C [26] or VEGF-D in
tumor cells [27] or recruitment of VEGF-C/D producing
macrophages at the tumor site [25]. COX-2 mediated pro-
motion of migratory [23], invasive [24], SLC stimulatory
[25] and VEGF-C and –D up-regulatory [25–27] functions
were primarily due to activation of the PGE receptor EP4
expressed by breast cancer cells [26, 27] as well as tumor
infiltrating macrophages [25], suggesting that both COX-2
and EP4 are good therapeutic targets for abrogating all
these PGE2 mediated functions. We validated this conten-
tion in a high COX-2 expressing syngeneic murine breast
cancer model, in which therapy with a COX-2 inhibitor or
two EP4 antagonists, equally inhibited tumor growth,
tumor-associated angiogenesis and lymphangiogenesis
and metastasis to the lymph nodes and the lungs [27], and
were also SLC-reductive in vivo [25]. Thus EP4 was
identified as a common target on cancer cells and
macrophages to abrogate multiple events: angiogenesis,
lymphangiogenesis, metastasis, and cancer stem cell
phenotype. It was, however, unclear whether tumor or
host derived PGE-2 had any direct effect on lymphatic
endothelial cells, and if so, whether EP4 receptors on
LECs played any role.
To answer these questions, we utilized lymphangiogen-
esis assays conducted in vitro and in vivo. In vitro assays
employed rat mesenteric lymphatic endothelial cells
(RMLEC), and also human dermal-derived LEC (HMVEC-
dLyAd) in some experiments. Proliferation, migration and
capillary-like tube formation by the LEC plated on growth
factor- reduced (GFR) Matrigel was quantified under vari-
ous experimental conditions including genetic manipula-
tion of the LEC or exposing LEC to cell-free conditioned
media from COX-2 high murine or human breast cancer
cell lines. We addressed whether: (a) the native tube
forming capacity of the LEC on Matrigel is dependent on
COX-2 or EP4 activity; (b) soluble products of COX-2-
expressing breast cancer cells stimulate tube formation by
the LEC; (c) proliferation, migration and tube forming cap-
acity of the LEC are stimulated by exogenous PGE2 or se-
lective EP4 agonists and if so, what are the underlying
signaling mechanisms. In additional experiments we uti-
lized a directed in vivo lymphangiogenesis assay (DIVLA)
devised in our laboratory [28, 29] to examine the roles of
exogenous PGE2 and EP4 agonists in promoting lymphatic
vessel outgrowth in nude mice. Results revealed that tumor
or host-derived PGE2 in the tumor micro-environment or
exogenous PGE2 or EP4 agonists can directly stimulate
lymphangiogenesis by activation of EP4 receptors on the
LEC via PI3K/Akt and Erk signaling pathways and
VEGFR-3 stimulation, so that EP4 antagonists may be use-
ful in the prevention and intervention of lymphatic metas-
tasis in breast cancer.
Methods
Reagents
DMEM-F12 medium, Fetal bovine serum (FBS), Dulbec-
co’s phosphate buffered saline (DPBS), trypsin, glutam-
ine, sodium pyruvate, and nonessential amino acids,
0.25% Trypsin-EDTA and Penicillin/Streptomycin used
in cell culture were obtained from Gibco, Life technolo-
gies (Burlington, ON). BD Falcon cell culture flasks
(75cm2), 6-well plates, 24-well
plates, growth factor reduced (GFR) Matrigel were
from BD Biosciences, San Jose, CA, USA. Antibodies
raised against VEGF-C (SC-1881), VEGF-D (SC-6314),
β-actin (SC-47778), CD-31 (SC-376764), Lyve-1 (SC-
80170), COX-2 (SC-1747) and rat EP4 shRNA (sc-
270389-SH) were from Santa Cruz Biotechnology, Santa
Cruz, CA. Prox-1 (11–002) antibody were from Angio-
bio, Del Mar, CA, USA. EP4 antibody (101775), PGE2,
PGE2 ELISA kit and, PGE1OH, L902 688 (both EP4
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agonist) and NS-398 (selective COX-2 inhibitor) and
were from Cayman, Ann Arbor, MI, USA. M-PER®
Mammalian Protein Extraction Reagent, HALT™ Prote-
ase Inhibitor Cocktail and Restore™ Plus Western blot
stripping buffer were from Pierce, Rockford, IL, USA.
Goat anti-rabbit IgG and goat anti-mouse IgG linked
HRP secondary antibodies were from Bio-Rad, Hercules,
CA. qRT-PCR primers were designed using Primer-3 site
and synthesized at the UWO Oligo factory. RNeasy Mini
Kit was from Qiagen, qScript™, cDNA Synthesis Kit and
PerfeCTa® Green SuperMix from Quanta Biosciences,
Gaithersberg, MD, USA; Indomethacin (non-selective
COX-1/COX-2 inhibitor) from Sigma (Oakville, ON,
Canada) and selective EP4 antagonist RQ15986 was a
gift from RaQualia Pharma Inc (Ask/At), Japan. Sources
of other reagents are given in parenthesis: Isoflurane
(Baxter, ON, Canada), rabbit anti-mouse Lyve-1 antibody
(Cat No 11–034, AngioBio, USA), Alexa Fluor 594
(Invitrogen, CA) anti rabbit secondary antibody, rat
monoclonal CD31 antibody (MEC 13.3, Santa Cruz Bio-
technology), Alexa Fluor 594 Goat Anti-Rat IgG (H + L),
Alexa Fluor 647 Donkey Anti-Rabbit IgG (H + L)
secondary antibodies, Vectashield solution (Vector
Laboratories, Burlington, ON). Cultrex® DIVAA Starter
Kit, CellSperse solution (Cat# 3450-048-05), wash buffer
(Cat# 3450-048-03), DIVAA™ 1X Dilution Buffer (Cat#
3450-048-07) were from Trevigen, MD, USA. O.C.T.
compound (Tissue-Tek*, Sakura Finetek USA, Inc.,
Torrance, USA). Taqman primers for murine LYVE-1
(Mm00475056_m1), CD31 (Mm01242584_m1) and β-
actin (4352933E) with TaqMan Gene Expression Assays
kit was from Applied Biosystems, USA. Endothelial Cell
Growth Medium EGM-2-MV Bulletkit (CC-3202) was
from Lonza, MO. USA.
Mice
Six weeks old Athymic nude female mice (Hsd: Athymic
Nude-Foxn1nu/Foxn1+), were obtained from Harlan la-
boratories, Indianapolis, IN and used at 8 weeks of age.
Cell lines and culture
Rat mesenteric lymphatic endothelial cell line (RMLEC) is
a spontaneously immortalized LEC isolated from rat mes-
enteric lymphatic endothelium [30], kindly provided by
Dr. Sophia Ran, Southern Illinois University School of
medicine. RMLEC (at passages 40–45) was grown in
DMEM supplemented with 10% FBS, 2mM glutamine, 50
U/ml penicillin and 50μg/ml streptomycin, 1mM Sodium
pyruvate, and 1mM nonessential amino acids at 37 °C and
10% CO2 [30]. RMLECs exhibited strong levels of expres-
sion of lymphatic endothelium specific markers, including
Prox-1, and Lyve-1. C3L5 is a COX-2 expressing and
highly metastatic murine breast cancer cell line, clonally
derived from a spontaneous mammary adenocarcinoma in
C3H/HeJ mice in our laboratory and is not commercially
available [31]. C3L5 cells were grown in advanced DMEM
medium without serum for 24h to collect conditioned
medium (CM) to study the functional effects of the CM on
the RMLEC. Human Dermal Lymphatic Microvascular
Endothelial Cells (HMVEC-dLyAd) (Cat. # CC-2810T25)
obained from Clonetics/Lonza (Walkersville, MO) and
maintained in an endothelial growth medium were used at
passage 5. Human breast cancer MDA-MB-231 cell line
(Cat. # ATCC® HTB 26™) (used at passage 3) obtained from
the ATCC and were grown in RPMI 1640 medium (Invi-
trogen, Burlington, ON) supplemented with 10% FBS, 100
U/ml penicillin, and 100μg/ml Streptomycin. MDA-MB-
231 cell CM was collected as above, to examine functional
effects on HMVEC-dLyAd cells.
LEC proliferation assay
Serum-starved RMLEC cells were seeded onto 96-well
tissue-culture microplates, treated with either PGE2
(10μM), PGE1OH (10μM) or C3L5 CM for 24 h, and a
cell proliferation ELISA BrdU (colorimetric) assay (Roche
Applied Science, Indianapolis, IN, USA) was performed.
LEC migration assay
Migration of RMLEC (wild-type or EP4 silenced) was
assessed with Boyden chambers using Transwell® inserts
(Corning Life Sciences, Oneonta, NY, USA) separated by a
polycarbonate membrane with 8 μm pore opening placed
within 24-well plates. A 300μl suspension of serum-
starved RMLEC cells at a concentration of 2 × 105/ml of
serum free medium were seeded in the upper chamber in
the presence of either PGE2, PGE1OH or C3L5- CM
while lower chamber had 2% charcoal-dextran stripped
FBS containing medium (free of PGE2). The assembled
chambers were then incubated for 24 h. After incubation,
the cells from the top of the membrane were wiped off
with cotton swabs whereas the migrant cells (from the
bottom of the membrane) were fixed with cold methanol,
stained with eosin/thiazine, and washed with distilled
water. The membranes were then dried, cut with surgical
blade, and fixed with mounting medium on a glass slide.
Direct microscopic counting at 40 ×magnification (Leica
DFC 295, Leica Microsystems, Germany) of cells that have
migrated to the lower side of the membrane was per-
formed and a mean value for each sample was calculated.
LEC tube formation assay
This assay was carried out with wild-type or EP4 silenced
RMLEC and native HMVEC-dLyAd cells under different
treatment conditions (as specified later in results) on GFR
Matrigel. Matrigel was thawed overnight at 4 °C, diluted
with cold sterile PBS in 1:1 ratio, and used to coat 24-well
culture plates (0.25 ml/well) and left at 37 °C for 6 h. After
polymerization, 40,000–60,000 cells/well, suspended in
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Advanced DMEM medium (Invitrogen) were added to
each well. Under native serum-free conditions very low
levels of tube formation occurred with wild-type RMLEC
at 12 h, gradually increasing with time (peaking between
24 and 30 h). The tempo of native tube formation in
HMVEC-dLyAd cells was somewhat slower peaking at 48
h. Under conditions of stimulation tube formation in both
native LECs was enhanced and sustained for 96 h. Pictures
of 10–15 random fields were captured in various experi-
ments using a Leica Microscope EC3 camera. The num-
bers of branching points or total tube lengths per unit
area were quantified using the NIH ImageJ software.
Branching points were considered as points from which
two or more tubes branched, as reported earlier [28]. This
method gave similar answers obtained by measurements
of total tube lengths per unit area [15]. Both methods were
used in the current study.
Western blot for Lyve-1, Prox-1, CD-31, COX-2, EP4, VEGF-C,
VEGF-D
RMLEC cells were washed with ice-cold DPBS (including
10nM NaF and 1mM Na3VO4) and lysed in M-PER® lysis
buffer supplemented with HALT™ protease inhibitor cock-
tail, 10mM NaF and 1mM Na3VO4. Cell lysates were cen-
trifuged and supernatant protein was quantified using the
BCA protein assay kit. Equal amounts of protein (25μg)
were separated on 12% SDS-PAGE gels and transferred to
a PVDF membrane. Membranes were blocked in 5% non-
fat milk in TBS (20mM tris-base, 0.14M NaCl, pH 7.8)
with 0.05% Tween-20 for one hour at room temperature
and probed for respective primary antibody (1:1000) at
4 °C, overnight. The membranes were washed with TBS
with 0.05% Tween-20 and incubated in HRP-conjugated
rabbit or mouse secondary antibodies (1:5000) for one
hour at room temperature. Peroxidase activity was de-
tected with enhanced chemiluminescence reagent.
Real time quantitative PCR for COX-2, EP4, VEGF-C, VEGF-D
Total RNA was extracted from RMLECs after specific
treatments as detailed in the results using RNeasy Mini
Kit. Respective cDNA was synthesised using qScript™
cDNA Synthesis Kit, and real time quantitative PCR
analysis was performed with BioRad thermocyler using
PerfeCTa® Green SuperMix and data analysed using CFX
Manager™ software for Rattus norvegicus β-actin, VEGF-
C, VEGF-D, COX2, EP4 gene expression. To determine
the relative levels of gene expression, the comparative
threshold cycle method (ΔCt) was use [32]. The final
mRNA levels were normalized according to their Ct
values from the standard curves and expressed in rela-
tion to respective β-actin/GAPDH level. The following
primer pairs have been used: β-actin forward (5-tag gtt
ttg tca aag aaa gg-3), reverse (5-tag gtt ttg tca aag aaa
gg-3); COX-2 forward (5-tac tac gcc tga gtt tct ga-3)
reverse (5-ggt gta gta gga gag gtt gg-3); VEGF-C forward
(5-ctt gaa aaa ctg ttg cca ca-3) reverse (5-aca aga gaa aaa
cct cag ct-3); VEGF-D forward (5-tat gaa cac aag cac ctc
ct-3) reverse (5-gac att gat ctt ctt ctg gg-3); EP4 forward
(5-ctg tgc tca gta aag cca ta-3) reverse (5-ctt tca gtt agg
tct ggc ag-3); GAPDH:forward (5’-tgattctacccacggcaagtt-3’)
reverse (5’-tgatgggtttcccattgatga-3’). The formed respective
amplicons were verified by running a DNA agarose gel
along with a standard DNA marker.
Knock down of EP4 gene in RMLEC
Rat EP4 shRNA plasmid (sc-270389-SH) and control
shRNA (sc-108066) plasmid were transfected stably into
RMLEC cells using an AMAXA machine and Amaxa Cell
Line Nucleofector Kit V (cat # VCA-1003) and protocol.
After transfection, cells were selected in RMLEC medium
with 10μg/ml puromycin and maintained with 300ng/ml
puromycin. The knockdown was validated with a qPCR,
showing 80% downregulation in EP4-Knock down (KD)
cells.
ELISA
ELISA was performed for PGE2 with RMLEC cell lysates
following the procedure specified in the PGE2 ELISA kits.
In brief RMLECs grown to reach 60% confluence under
specific treatment conditions were washed with PBS and
incubated in SFM for 12h. Cells were washed with PBS
twice and incubated with trypsin and the cell suspension
were centrifuged and re-suspended in the media and the
cell number was calculated using a cell counter. Cells were
re-centrifuged to obtain the cell pellet which was lysed
with RIPA lysis buffer and protein extracted. The protein
extract for each of the conditions in triplicate was incu-
bated in the ELISA plates and ELISA performed for PGE2
with respective standards supplied along with the kit. The
experiment was performed in triplicate in two separate ex-
periments and the concentrations of the PGE2 were ex-
trapolated from the standard curve.
Directed In-vivo lymphangiogenesis assay (DIVLA)
This assay was conducted as reported by us [29]. In brief
6 weeks old athymic nude female mice were allowed to
acclimatize for 2 weeks, maintained on standard mouse
chow and tap water on a 12 h light/dark cycle. Sterile
angioreactors were pre-chilled at 4° C and filled with 20μl
of either growth factor reduced Basement Membrane
Extract (BME) (Cat# 3450-048-02, Trevigen, MD, USA)
alone, or in combination with PGE2 (10μM) or EP4 ago-
nists PGE1OH and L 902688 (10uM) or VEGF-C (20ng)
(2179-VC-025, R&D Systems, CA), the latter serving as
positive control for lymphangiogenesis and angiogenesis.
Angioreactors were incubated at 37 °C for 1 h to allow
BME gel formation, before subcutaneous implantation
into the mice. Mice were anaesthetized with isoflurane.
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Four angioreactors containing the same agents were im-
planted per mouse, two on each side of the dorsal flank re-
gion, and 2 mice were used per condition. After a period
of 10 days, mice were euthanized and the angioreactors
were retrieved and used for three purposes as reported
earlier [29]. All the angioreactors were retrieved without
severing the ingrowing vessels and excising the rest of the
tissues with fine scissors. One angioreactor was flash-
frozen immediately with dry ice for making cryosections.
The other three were used to collect cellular contents and
conduct lymphatic in-growth assay and RNA extracted for
real time gene expression. Three approaches were utilized
for measuring angiogenesis/lymphangiogenesis: (i) Lyve-1,
prox-1 and CD31 proteins by immunoflurometry of cell
lysates; (ii) Lyve-1, prox-1 and CD31 mRNA by qPCR of
extracted RNA; (iii) a visual quantification of lymphatic
and blood vessel in-growth into the angioreactors from
double labeling for Lyve-1, or Prox-1, (LEC markers) and
CD31 (blood vessel endothlial marker) using the hot spot
method [25, 27].
Statistical analysis
Data are presented as mean ± standard error (SE) for each
treatment compared to the control. Graph-pad Prism5
software were used to analyze the data with t-test. Differ-
ences between two treatment groups were accepted as
significant at p < 0.05.
Results
Expression of LEC markers by RMLEC
The RMLECs were tested for the expression of the lymph-
atic markers Lyve-1, prox-1 and angiogenesis marker
CD31 by western blot. The cells were positive for Lyve-1,
prox-1 (Fig. 1a), and negative for CD-31 (Fig. 1b). These
Fig. 1 Effects of EP4 ligands and C3L5-CM on proliferation and migration of RMLEC. Western blots for a Lyve-1, Prox-1 and b CD-31 were performed
with RMLEC lysate. For both Lyve-1 and Prox-1, mouse lung extract and MCF-7 cell lysate were used as respective + ve and –ve controls. For CD-31,
HUVEC and HEK-293 cell lysates were used as respective + ve and –ve controls. c proliferation (BrdU incorporation) and d trans-well migration assays
were performed to assess the effects of PGE2, PGE1OH and C3L5-CM on RMLEC. Error bars represent mean ± SEM of three different experiments. (*)
represents p < 0.05
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findings validated the data reported by the originator of
the cell line [30]. They also expressed all EP receptors (not
shown).
The effects of PGE2, EP4 agonist and C3L5-CM on prolifer-
ation and migration of RMLECs
Lymphangiogeneisis in vivo involves proliferation, migra-
tion and organization of LEC into complex tubular
structures that can crudely be recapitulated in vitro in
individual assays. Based on preliminary experiments
showing that both PGE2 and PGE1OH stimulated these
events equally at 10 μM and 20 μM concentrations, we
used the lower concentrations in our assays except with
EP4 KD cells (shown later, in which case we used the
higher concentration). Presence of non-selective EP lig-
and PGE2 (10μM), EP4 agonist PGE1-OH (10μM) and
24h C3L5-CM significantly stimulated the proliferation
(Brdu uptake for 24 h) (Fig. 1c) and migration (24h in
trans-well) (Fig. 1d) of RMLEC in media containing 2%
charcoal-stripped FBS.
Tube formation by RMLEC under various treatment
conditions: Effects of PGE2, EP4 agonist, C3L5-CM, COX1/
COX-2 inhibitor and EP4 antagonist
RMLECs cultured overnight in advanced-DMEM with
2% FBS were washed and seeded on GFR Matrigel-
Fig. 2 Representative photo-micrographs of RMLEC tubular network formation in response to different agents. a Tube formation were measured
on GFR-Matrigel at 30 h in the presence of BSA(control), COX-1/2 inhibitor indomethacin (20μM), COX-2 selective inhibitor NS-398 (20μM), EP4
antagonist RQ-15986 (1μM), PGE2 (10μM), EP4 agonist PGE1-OH (10μM), and 24h C3L5-CM. Bars equal 100 μm. b Quantification of the number of
branching points in the captured area representing 10 different fields of view, (FOV) for each experimental condition. Each bar graph represents
each experimental condition. Error bars represent mean ± SEM of three different experiments. (**) represents p < 0.001
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coated plates (40,000 cells per well), and tube formation
examined at 24–96 h. Under native conditions tube for-
mation was sparse at 12 h, but evident at 24 h. This was
further stimulated by EP4 agonist PGE1OH (10μM) or
PGE2 (10μM) or cell-free C3L5-CM, whereas non select-
ive COX-1/COX-2 inhibitor Indomethacin (20μM), select-
ive COX-2 inhibitor NS-398 (20μM) and selective EP4
antagonist RQ15986 (1μM) abrogated the native tube
formation (Fig. 2a). C3L5-CM collected from C3L5 cells
pre-treated for 24h with COX-2 inhibitor NS-398 (20μM)
had no stimulatory activity (not shown). Since C3L5 cells
secreted VEGF-C/D as well as PGE2 which are abrogated
with COX-2 inhibitor and C3L5-CM collected after pre-
treatment of C3L5 cells may have unspent COX-2 inhibi-
tor, we could not definitely identify the reasons for the
loss of stimulation. This prompted us to interrogate the
roles of exogenous PGE2 or EP4 agonist on tubulogenesis.
Quantification of tubulogenesis given as the numbers
of branching points under each condition is presented
in (Fig. 2b). These results indicated that Matrigel in-
duced tube formation was dependent on COX-2 and
EP4 activity of the LEC. This is consistent with our
findings that LEC expressed very little COX-2 in mono-
layer cultures but both COX-2 and EP4 were upregu-
lated in the presence of Matrigel (data not shown).
Additional presence of PGE1OH (10μM) or PGE2
(10μM) or C3L5-CM to the RMLECs restored tube for-
mation in the presence of the above inhibitors or antag-
onists (Fig. 2a). That EP4 agonist could restore tube
formation in the presence of the antagonist suggested
that the antagonist did not completely block all EP4 re-
ceptors. This led to the subsequent experiments explor-
ing the EP4 dependence of tubulogenesis as presented
later using EP4 KD RMLEC.
Fig. 3 Representative micrographs of HMVEC-dly tubular network formation in response to different agents. a Tube formation were measured on
GFR-Matrigel at 24 h in the presence of SFM or RPMI medium (control), MDA-MB-231 CM, PGE2 (1μM), EP4 agonists PGE1OH (1μM), and L-902688. Bars
equal 100 μm. b Quantification of the total tube length in the captured area at 10 different field of view, (FOV) for each experimental condition as
determined by ImageJ. Each bar graph represents each experimental condition. Error bar represents mean ± SEM of three different experiments. (**)
represents p < 0.001. Tubulogenesis quantitated by innumeration of branching points gave identical results (not shown)
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Tube formation by human dermal LEC (HMVEC-dly) under
various treatment conditions
We tested whether some of the results noted above
in RMLEC were reproducible with human LEC
(HMVEC-dLyAd) in tubulogenesis assays. In this case
we used cell free conditioned medium from a high
COX-2 expressing MDA-MB-231 cells [26]. Represen-
tative images and quantification at 24 h are presented
respectively in Fig. 3a and b. Addition of MDA-MB-
231-CM, PGE2 and two EP4 agonists (PGE1OH and
L-902688) all markedly stimulated tubulogenesis (p <
0.001), simulating the results noted above with
RMLEC.
Migration and tube formation by EP4 KD RMLEC under
different treatment conditions
EP4 shRNA transfected RMLECs exhibited about 80%
EP4 knockdown (KD) as demonstrated by qPCR rela-
tive to mock (scrambled shRNA)-transfected (control)
cells (Fig. 4a). EP4 KD cells exhibited 98–99% viability,
as assessed by trypan blue exclusion. Both mock and
EP4 KD cells were subjected to migration (24 h) and
tube formation (30 h) assays in the presence or absence
of PGE2 (20μM), PGE1OH (20μM) or C3L5-CM. While
all these agents significantly stimulated migration in
control cells (Mock) none of these agents could signifi-
cantly restore migration of EP4 KD cells to control
Fig. 4 Effects of EP4 knock-down on migration and tube formation by RMLEC. a Real-time qPCR of EP4 mRNA expression (normalized to GAPDH)
in EP4 knock-down RMLEC. b Cellular migration of EP4 KD RMLEC in response to PGE2 (20μM), EP4 agonist PGE1OH (20μM), and 24h C3L5-
CM. c Tube formation by EP4 KD RMLEC on GFR-Matrigel at 24 h in the presence of the stimulating agents at same concentrations used for
migration assay. Bars equal 100 μm. d Quantification of the number of branching points in the captured area at 10 different FOV for each
experimental condition as determined by imageJ. Error bar represents mean ± SEM of three different experiments. (*) and (**) represent p < 0.05 and
p < 0.001 respectively
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levels (Fig. 4b). The number of migrant cells were not sig-
nificantly different from those in the absence of these
agents. Tube formation in control cells (shown in Fig. 4c)
was similar to those of untransfected cells (not shown).
EP4 KD cells showed significant loss of ability for tubulo-
genesis as compared to control cells (Fig. 4c). Addition of
non-selective EP ligand PGE2 (10μM), selective EP4 agon-
ist PGE1OH (10μM) or C3L5-CM to the EP4 KD cells
failed to significantly restore tube formation (morphology
in Fig. 4c, quantification in Fig. 4d). These results establish
that migration and tubulogenesis by RMLEC were EP4
dependent.
Effect of the C3L5-CM and EP ligands on moleluclar pro-
file of RMLEC
Since in our preliminary differential gene array experiment
(data not shown) we observed significant upregulation of
a number of molecules including COX-2, VEGF-C, VEGF-
D and EP4 in C3L5 CM treated RMLEC, we tested the ex-
pression of these molecules by qRT-PCR and western blot.
Figure 5a reveals that mRNA levels of the above molecules
were significantly upregulated by C3L5-CM. Figure 5b
shows upregulation of COX2, VEGF-C, VEGF-D and EP4
also at protein levels. In support of COX2 upregulation,
these cells also exhibited an increase in endogenous PGE2
Fig. 5 Effects of C3L5-CM, PGE2 and PGE1OH on molecular profile of RMLEC. a Relative mRNA level of COX-2, EP4, VEGF-C, VEGF-D in RMLEC
treated with C3L5 -CM for 24 h compared to control. b Western blots with cytoplasmic extracts obtained from above treated cells showing the
expression of EP4, COX-2, VEGF-C, VEGF-D at the protein level. c Cytoplasmic PGE2 level (measured by ELISA) in C3L5-CM treated RMLEC compared to
control. d Relative COX-2, VEGF-D and EP4 mRNA expression (normalized to GAPDH) in untreated (control) or PGE2 and PGE1OH treated
RMLEC. e Western blots of COX-2, VEGF-D and EP4 protein in untreated or PGE2 and PGE1OH treated RMLEC. Error bar indicates mean ± SEM.
(*) and (**) indicates p values < 0.05 and <0.001 respectively
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production as shown with ELISA in the cell lysate
(Fig. 5c). Since C3L5-CM was known to contain PGE2
in addition to other molecule such as VEGF-C and D,
we could not distinguish amongst these molecules
which exerted the effects. For this reason, we treated
the cells directly with PGE2 and also the selective EP4
ligand PGE1OH. The results for mRNA expression are
shown in Fig. 5d (qRT-PCR). Both these ligands upreg-
ulated VEGF-D and COX-2 but not VEGF-C. EP4 re-
ceptor was also upregulated only with PGE2 but not
PGE1OH treatment. These data are supported by west-
ern blots (Fig. 5e).
EP4 mediated signaling events in tubulogenesis
While both EP2 and EP4 receptors share signaling by
cAMP pathway, EP4 also known to utilize non-
canonical PI3K/Akt and Erk pathways [33]. For this
reason we examined Akt and Erk phosphorylation in
RMLEC following both PGE2 and EP4 agonist
(PGE1OH) treatment. Both Akt and Erk1/2 phosphor-
ylation were stimulated at 24 h (relative to total Akt or
total Erk) with both ligands (Fig. 6a, b). Whether these
pathways were essential for agonist mediated tubulo-
genesis was examined in RMLEC treated with PI3K/
Akt inhibitor (LY294002, wortmannin) and Erk inhibi-
tor (U0126). Both pathway inhibitors effectively blocked
tubulogenesis in the presence of the above ligands indi-
cating the requirement of both pathways in EP4 mediated
tubulogenesis (Fig. 7a, b). However these inhibitors also
significantly reduced native tubulogenisis on Matrigel
indicating the obligatory need of both pathways for
Matrigel-induced tubulogenesis.
Since VEGF-D was upregulated in LEC following both
PGE2 and PGE1OH treatment (Fig. 5d, e), it was likely
that EP4 mediated tubulogenesis noted above was an in-
direct result of VEGF-D production and its binding to
its receptor VEGFR-3. To test this hypothesis, we exam-
ined EP4 agonist mediated tubulogenesis in the presence
of VEGFR-3 blocking antibody. Presence of the antibody
significantly blocked native tube formation and tubulo-
genesis induced by PGE2/ PGE1OH (Fig. 8), suggesting
the obligatory role of VEGFR-3 in tubulogenesis in
RMLEC.
In vivo angiogenesis and lymphangiogenesis assay
Directed in-vivo angiogenesis and lymphangiogenesis
assays in mice [29] was performed by implanting the
angioreactors with VEGF-C, PGE2, and EP4 agonists
PGE1OH or L-902,688 mixed in BME. After ten days,
the angioreactors were removed to visualize their gross
appearances (Fig. 9a) which revealed red colors (crude
evidence of angiogenesis) variably in all ligand contain-
ing angioreactors. Their contents were used to quantify
the lymphatic and blood vascular in-growth as given by
the expression of lymphatic and vascular endothelial
cell markers using qPCR (of mRNA) (Fig. 9b) and spec-
trofluorometry (of proteins) (Fig. 9c). VEGF-C (used as
the internal positive control), PGE2 and both EP4
agonists increased the protein and mRNA expression
levels of Prox-1 and Lyve-1. Histological examination
of angioreactors were carried out by dual immune-
staining of cryo-sections for Lyve-1, or Prox-1, and CD-
31. Inclusion of VEGF-C, PGE2 (10μM) or EP4 agonists
PGE1OH (10μM) or L-902688(10μM) in the angioreac-
tors markedly increased the incidence of in-growing
lymphatics (stained for Lyve-1or Prox-1) and to a
smaller extent blood vessels (stained for CD31) (Fig. 10)
into the angioreactors.
Fig. 6 Effects of EP ligands on PI3K/Akt and Erk phosphorylation in RMLEC. Western blot analysis of (a). Akt and (b). Erk1/2 activation in RMLEC
following treatment with PGE2 and PGE1OH for a period of 24 h. Stimulation of phosphorylation of Akt at Ser 473 and Erk1/2 were observed
compared to control, untreated cells. Total Akt and total Erk1/2 confirmed the equivalent loading of lanes. (c) and (d). Densitometric analysis
revealed that phosphorylation of both pathways was significantly induced after the treatments. (*) indicates p values < 0.05
Nandi et al. BMC Cancer  (2017) 17:11 Page 10 of 17
Discussion
Inflammation is believed to play an important role during
all aspects of tumor development and tumor progression
[34]. It is also an important promoter of lymphangiogen-
esis. There are possibly many common inflammation-
associated mediators participating in both events. Of
these, the role of tumor or host derived PGE2 in lymphan-
giogenesis has not been well-defined. Among the multiple
tumor cell products stimulating breast cancer associated
lymphangiogenesis, we have earlier reported the roles of
VEGF-C and VEGF-D produced by COX-2 expressing
breast cancer cells in the human [26] as well as in the
mouse [27]. Furthermore, VEGF-C and –D production by
tumor infiltrating macrophages also contributed to lym-
phangiogenesis in our murine breast cancer model [25].
In addition COX-2 expression by breast cancer cells can
upregulate the expression of the chemokine receptor
CCR7 via activation of EP2/EP4 receptors [35]. We have
shown that a molecular cross-talk between breast cancer
cells and LEC via the CCL21/CCR7 chemokine/ chemo-
kine receptor axis plays a major role in breast cancer asso-
ciated lymphangiogenesis [15]. In the present study we
used a rat mesenteric lymphatic endothelial cell line which
expressed the lymphatic markers Lyve-1 and Prox-1 but
not the angiogenesis marker CD31 and a COX-2 express-
ing murine breast cancer cell line C3L5 to study the roles
Fig. 7 Effects of PI3K/Akt and Erk inhibitors on tube formation by RMLEC. a Representative photo-micrographs of RMLEC tubular network
formation in response to PGE2 and PGE1OH in presence of PI3K/Akt inhibitors (Ly294002 and wortmanin) or Erk inhibitor (U0126). Bars equal
100 μm. b Quantification of branch points of tubular structures corresponding to (a) as determined by ImageJ. (***) represents p = 0.0001
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of soluble tumor cell products on lymphangiogenesis.
Tube formation by the LEC in vitro is a complex morpho-
logical event that only partially recapitulates lymphangio-
genesis in vivo, requiring cell migration, alignment and
formation of three-dimensional structures that mimics
lymphatic capillaries. In spite of limitations, it is a valuable
in vitro model to dissect the mechanisms without the in-
fluence of confounding factors that can modulate lym-
phangiogenesis in vivo in a positive or a negative manner
[28]. We had earlier shown that C3L5 cells secrete PGE2
and lympangiogenic factors VEGF-C and VEGF-D [27].
To dissect the roles of tumor-derived PGE2 and EP4 re-
ceptors on the LEC in the lymphangiogenic events, we
measured the effects of C3L5- CM, exogenous PGE2 and
EP4 agonists on LEC proliferation, migration and tubulo-
genesis, showing a stimulation of all the three events with
all of the above agents. Conversely, natural tube formation
by the LEC on GFR-Matrigel was abrogated in presence of
COX-1/2 inhibitor Indomethacin, COX-2 inhibitor NS-
398 and EP4 antagonist RQ15986, indicating that
Matrigel induced tubulogenesis was dependent on
COX-2 and EP4 activity of the LEC. Tubulogenesis was
largely restored by the additional presence of PGE2 or
EP4 agonist or C3L5-CM. These findings taken to-
gether reinforce the stimulatory roles of tumor-derived
PGE2 in breast cancer associated lymphangiognesis by
activation of EP4 expressed by the LEC. We have repli-
cated some of these findings using human dermal LEC
(HMVEC-dly) and a COX-2 expressing human breast
cancer cell line MDA-MB-231. These in vitro results
using the LECs and breast cancer cells suggest that
PGE2 is another tumor-derived molecule that can dir-
ectly stimulate lymphangiogenesis by binding to EP4
on the LEC.
C3L5-CM contains multiple lymphangiogenic molecules
including PGE2, VEGF-C and VEGF-D [27] that can
Fig. 8 Effects of VEGFR-3 neutralizing antibody on tube formation by RMLEC. a Representative images of RMLEC tube formation in response to
treatment with VEGFR-3 neutralizing antibody (5μg/ml). Presence of PGE2 or PGE1OH could not reverse the VEGFR-3 antibody mediated inhibition
of tube formation. Bars equal 100 μm. b Quantification of branch points of tubular structures corresponding to (a) as determined by ImageJ. Data
are presented as mean ± SEM. (***) represents p = 0.0001; (****) represents p < 0.0001
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directly act on the LEC. Similarly, MDA-MB-231-CM
contains at least two classes of stimulatory molecules
namely VEGF-C and PGE2, both produced in a COX-2
dependent manner [26]. While VEGF-C and VEGF-D can
stimulate LEC growth and tubulogenesis by binding to
VEGFR-3 [28], PGE2 could promote these events by acti-
vating EP4. The fact that shRNA-mediated EP4 silencing
of RMLEC made them refractory to the stimulation by the
C3L5-CM or PGE2/EP4 agonist (Fig. 4) reinforced the ob-
ligatory role of EP4 in lymphangiogenesis.
PGE2 in the tumor microenvirnment in vivo can be a
product of tumor cells or host cells such as macro-
phages. Indeed this is also true for the lymphangiogenic
factors VEGF-C or VEGF-D [28]. EP4 activation stimu-
lates cAMP/PKA pathway shared by EP2, and also stim-
ulates non-canonical PI3K/Akt and Erk1/2 pathways not
shared by EP2 [33]. We show here that PGE2 or EP4
agonist mediated stimulation of tubulogenesis in the
RMLEC was dependent on both PI3K/AkT and Erk
pathways. Unexpectedly, C3L5-CM also stimulated the
Fig. 9 Expression of angiogenesis and lymphangiogenesis markers in angioreactors obtained at DIVLA a. Macroscopic images of angioreactors
collected with surrounding tissues. b Quantitative real-time PCR analysis of Lyve1 Prox-1 and CD31 mRNA expression in the cellular contents of
angioreactors. Expression levels are normalized to actin. c relative fluorescence analysis of Lyve1, Prox1, and CD31 proteins as expressed by mouse
lymphatic and blood vascular endothelial cells recruited into the angioreactors. Data are presented as mean ± SEM. (*) indicates significant difference
p < 0.05 and (**) indicates p < 0.001
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production of PGE2, VEGF-C, VEGF-D by the RMLEC
and uptregulated COX2 and EP4 in RMLEC (Fig. 5).
Similarly PGE2 or EP4 agonist upregulated VEGF-D in
RMLEC. Thus VEGF-C and VEGF-D in turn could lead
to an autocrine growth stimulation by activation of
VEGFR-3 on the LEC. This contention was fully vali-
dated by the fact that EP4 agonist mediated tubulogen-
esis was abrogated in presence of VEGFR-3 blocking
antibody. These results lead to the proposal that there is
a molecular cross talk between breast cancer cells or
host macrophages and LEC involving EP4/PGE2 axis
and VEGF-C or D/VEGFR-3 axis (schema presented in
Fig. 11).
In the present study we validated the roles of PGE2 and
EP4 in lymphangiogenesis in vitro and in vivo studies in
nude mice using directed in vivo lymphangiogenesis assay
(DIVLA) previously developed in our lab [29]. Inclusion
of PGE2 and two EP4 agonists in the angioreactors signifi-
cantly increased lymphangiogenesis and to a minor extent
angiogenesis, identified by three approaches: expression of
lymphatic endothelial marker molecules Prox-1 and Lyve-
1 and vascular endothelial marker molecule CD31 at the
mRNA and protein levels; and a dual immunostaining of
lymphatics for Lyve-1 or prox-1 and blood vessels for
CD31. Thus we confirmed the lymphangiogenic as well as
angiogenic capacity of PGE2 and EP4a in vivo. Our results
support a recent report that PGE2 promotes angiogenesis
through EP4 activation [36].
All the above results cumulatively demonstrate the
roles of tumor as well as host-derived PGE2 in inducing
lymphangiogenesis, at least in part, by activating EP4
on lymphatic endothelial cells. Since EP2 and EP4 share
cAMP signaling pathways, we believe that EP2 is an-
other player. Absence of highly selective EP2 agonists
has precluded testing whether EP4 is more lymphangio-
genic than EP2.
We found in multiple studies that EP4 on breast can-
cer cells accounts for numerous COX-2 mediated mech-
anisms in breast cancer progression: increased migration
and invasion [22–24], VEGF-C/D upregulation [26, 27]
Fig. 10 Immuno-histological quantification of lymphatics and vascular endothelial cells in angioreactor contents based on double labeling. (Upper
panel). Immunofluorescence localization of CD31 (green), Lyve1 (red), and Prox1 (red) in serial sections of angioreactors containing BME alone or
BME + VEGF-C (5ng/200μl), BME + PGE1OH (10μM), BME + PGE2 (10μM), BME + L-902688(10μM). Images were captured using the confocal
microscope. (lower panel). “Hot spot” scores for CD31-Lyve1 and CD31-Prox1 were calculated by means of Image J (40× magnification). Data are
presented as mean of “hot spot” ± SEM. Scale bar equals 50 μm. (*) indicates significant difference p < 0.05 and (**) indicates p < 0.001 relative to
BME (control) for each marker
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promotion of tumor-associated angiogenesis and lym-
phangiogenesis in vivo [27] and finally, induction of
stem-like cells [37, 38]. Using the COX-2 expressing
murine C3L5 breast cancer model, we found that an
EP4 antagonist at nontoxic doses abrogated tumor
growth, tumor associated angiogenesis and lymphangio-
genesis, and metastasis to the lymph nodes and the
lungs, and an abrogation of stem-like cell functions in
vitro and in vivo [25, 27]. Present results reveal that EP4
is also a common target on the LEC for blocking direct
effects of tumor or host derived PGE2 on lymphangio-
genesis. Since long term use of COX-2 inhibitors are re-
ported to increase thrombo-embolic side effects in
patients [39–41], there is a continuous search for drugs
targeting molecules downstream of COX-2, that may
spare cardio-protective prostacyclins such as PGI2 [42].
We suggest that EP4 antagonists may satisfy this re-
quirement and can be utilized in the intervention of
lymphatic metastasis in breast cancer.
Conclusions
Present results add a new dimension in translational
breast cancer research. EP4 is a receptor shared by
tumor cells [26, 27] as well as host cells e.g., NK cells
[43], macrophages [25] and LEC (current study), re-
sponsible for multiple COX-2 mediated cellular pro-
cesses responsible for breast cancer progression and
metastasis (Schema presented in Fig. 11). Relative
physiological redundancy of EP4 receptor due to shar-
ing many of its functions by EP2 via cAMP pathway
makes it a logical therapeutic target in breast cancer.
In a phase1/II study of arthritis patients, EP4 antago-
nists at therapeutic doses have shown high tolerability
(Dr Yukinori Take, and Dr. Akihiro Furuta, Ask/At,
Japan, personal communication) deserving clinical
testing as an adjuvant in breast cancer.
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Fig. 11 Proposed roles of PGE2-EP4 in breast cancer associated lymphangiogenesis. Molecular cross-talk amongst tumor cells, host cells
(macrophages) and LECs: Both tumor and host cells produce PGE2 and VEGF-C/D. PGE2 binding to EP4 receptors on LEC directly promote
lymphangiogenesis (via proliferation migration and tubulogenesis) following activation of PI3K/Akt and Erk signaling. EP4 activation also
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lymphatic vessels by binding to VEGFR-3 on LEC
Nandi et al. BMC Cancer  (2017) 17:11 Page 15 of 17
Acknowledgments
This study was supported by grants from the National Science and
Engineering Research Council (NSERC) of Canada and the Ontario Institute of
Cancer Research (OICR) to PKL. Gift of EP4 antagonist RQ15986 by Ask/At,
Japan is gratefully acknowledged.
Funding
Supported by grants from the National Science and Engineering Research
Council (NSERC) of Canada and the Ontario Institute of Cancer Research
(OICR) to PKL.
NSERC: design of the study and collection, analysis, and interpretation of
data and in writing the manuscript. OICR: design of the study.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Authors’ contributions
PN: Designed the study, performed most of the experiments including data
acquisition and interpretation, wrote and revised the manuscript. GVG:
Contributed partial data for Figs. 1, 5, 9 and 10 and contributed to the initial
draft of the manuscript. MM: Contributed to experiments in Figs. 9 and 10.
XX: Contributed to experiments in Figs. 9 and 10. ETF: Contributed to
experiments in Fig. 3. PKL: Conceived and supervised the study and revised
the manuscript. All authors read and approved the final manuscript.
Competing interests




Studies using athymic mice was approved by the Institutional Animal Care
Committee, in full compliance with the guidelines set by the Canadian




1Department of Anatomy and Cell Biology, University of Western Ontario,
London, Ontario N6A5C1, Canada. 2Department of Oncology, University of
Western Ontario, London, Ontario N6A5C1, Canada. 3Children’s Health
Research Institute, Schulich School of Medicine and Dentistry, University of
Western Ontario, London, Ontario N6A5C1, Canada. 4Department of Biology,
Brandon University, Brandon, Manitoba R7A 6A9, Canada.
Received: 26 May 2016 Accepted: 16 December 2016
References
1. Schlag PM, Veronesi U. Recent results in cancer research: lymphatic
metastasis and sentinel lymphonodectomy. New York: Springer; 2000.
2. Wong SL, Chao C, Edwards MJ, Carlson DJ, Laidley A, Noyes RD, et al.
Frequency of sentinel lymph node metastases in patients with favorable
breast cancer histologic subtypes. Am J Surg. 2002;184(6):492–8.
3. Yasuda K, Inomata M, Fujii K, Shiraishi N, Adachi Y, Kitano S. Superficially
Spreading Cancer of the Stomach. Ann Surg Oncol. 2002;9(2):192–6.
4. Fujii T, Tabe Y, Yajima R, Yamaguchi S, Tsutsumi S, Asao T, et al. Process of
distant lymph node metastasis in colorectal carcinoma: Implication of
extracapsular invasion of lymph node metastasis. BMC Cancer. 2011;11:216.
doi:10.1186/1471-2407-11-216.
5. Zhang Z, Helman JI, Li LJ. Lymphangiogenesis, lymphatic endothelial cells
and lymphatic metastasis in head and neck cancer–a review of
mechanisms. Int J Oral Sci. 2010;2(1):5–14. doi:10.4248/IJOS10006.
6. Izbicki JR, Passlick B, Hosch SB, Kubuschock B, Schneider C, Busch C, et al.
Mode of spread in the early phase of lymphatic metastasis in non-small-cell
lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc
Surg. 1996;112:623–30.
7. Van Meurs H, Visser O, Buist MR, Ten Kate FJ, van der Velden J. Frequency of
pelvic lymph node metastases and parametrial involvement in stage IA2
cervical cancer: a population-based study and literature review. Int J
Gynecol Cancer. 2009;19(1):21–6. doi:10.1111/IGC.0b013e318197f3ef.
8. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al.
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.
Hum Pathol. 2000;31(5):578–83.
9. Haller H, Mamula O, Krasevic M, Rupcic S, Fischer AB, Eminovic S, et al.
Frequency and Distribution of Lymph Node Metastases in Epithelial Ovarian
Cancer Significance of Serous Histology. Int J Gynecol Cancer. 2011;21:2.
10. Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic
metastasis in breast cancer. Pathophysiology. 2010;17(4):229–51. doi:10.
1016/j.pathophys.2009.11.003.Epub2009Dec.
11. Bhattacharjee RN, Timoshenko AV, Cai J, et al. Relationship between
cyclooxygenase-2 and human epidermal growth factor receptor 2 in
vascular endothelial growth factor C up-regulation and lymphangiogenesis
in human breast cancer. Cancer Sci. 2010;101:2026–32.
12. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in
health and disease. Cancer Cell. 2002;1:219–27.
13. Christiansen A and Detmar M. Lymphangiogenesis and Cancer. Genes
Cancer. 2011. doi:10.1177/1947601911423028.
14. Ou JJ, Wei X, Peng Y, Zha L, Zhou RB, Shi H, et al. Neuropilin-2 mediates
lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent
signaling. Cancer Lett. 2015;358(2):200–9. doi:10.1016/j.canlet.2014.12.046.
15. Tutunea-Fatan E, Majumder M, Xin X, Lala PK. The role of CCL21/CCR7
chemokine axis in breast cancer-induced lymphangiogenesis. Mol Cancer.
2015;14:35. doi:10.1186/s12943-015-0306-4.
16. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in
inflammation, cancer, and development. Oncogene. 1999;18:7908–16.
17. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor
progression. Cancer Metastasis Rev. 2007;26:525–34.
18. Harris RE. COX-2 blockade in cancer prevention and therapy. Totowa:
Humana Press; 2003.
19. Lyons TR, Borges VF, Betts CB, Guo Q, Kapoor P, et al. Cyclooxygenase-2–
dependent lymphangiogenesis promotes nodal metastasis of postpartumbreast
cancer. J Clin Invest. 2014;124(9):3901–12. doi:10.1172/JCI73777.
20. Lala PK, Parhar RS, Singh P. Indomethacin therapy abrogates the
prostaglandin-mediated suppression of natural killer activity in tumor
bearing mice and prevents tumor metastasis. Cell Immunol. 1986;99:108–18.
21. Lala PK, Al-Mutter N, Orucevic A. Effects of chronic indomethacin therapy
on the development and progression of spontaneous mammary tumors in
C3H/HEJ mice. Int J Cancer. 1997;73:371–80.
22. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine
mammary tumor progression by reducing tumor cell migration,
invasiveness and angiogenesis. Int J Cancer. 2001;93:497–506.
23. Timoshenko AV, Xu G, Chakrabarti S, et al. Role of prostaglandin E2
receptors in migration of murine and human breast cancer cells. Exp Cell
Res. 2003;289:265–74.
24. Timoshenko AV, Lala PK, Chakraborty C. PGE2-mediated upregulation of
iNOS in murine breast cancer cells through the activation of EP4 receptors.
Int J Cancer. 2004;108:384–9.
25. Majumder M, Liu L, Gannareddy GV, Lala PK. Prostaglandin E2 receptor EP4
as the common target on cancer cells and macrophages to abolish
angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Cancer Sci. 2014;105:1142–51. doi:10.1111/cas.12475.
26. Timoshenko AV, Chakraborty C, Wagner GF, et al. COX-2-mediated
stimulation of the lymphangiogenic factor VEGF-C in human breast cancer.
Br J Cancer. 2006;94:1154–63.
27. Xin X, Majumder M, Gannareddy GV, Mohindra V, Maruyama T, Lala PK.
Targeting COX-2 and EP4 to control tumor growth, angiogenesis,
lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast
cancer model. Lab Invest. 2012;92:1115–28. doi:10.1038/labinvest.2012.90.
28. Majumder M, Tutunea-Fatan E, Xin X, Rodriguez-Torres M, Torres-Garcia J,
Wiebe R, et al. Co expression of alpha9beta1 integrin and VEGF-D confers
lymphatic metastatic ability to a human breast cancer cell line MDA-MB-
468LN. PLoS One. 2012;7, e35094.
29. Majumder M, Xin X, Lala PK. A practical and sensitive method of
quantitating lymphangiogenesis in vivo. Lab Invest. 2013;93:779–91.
30. Whitehurst B, Eversgerd C, Flister M, Bivens CM, Pickett B, Zawieja DC, Ran S.
Molecular profile and proliferative responses of rat lymphatic endothelial
cells in culture. Lymphat Res Biol. 2006;4(3):119–42.
Nandi et al. BMC Cancer  (2017) 17:11 Page 16 of 17
31. Lala PK, Parhar RS. Eradication of spontaneous and experimental
adenocarcinoma metastases with chronic indomethacin and intermittent IL-
2 therapy. Int J Cancer. 1993;54:677–84.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods.
2001;25(4):402–8.
33. Fujino H, Salvi S, Regan JW. Differential regulation of phosphorylation of the
cAMP response element-binding protein after activation of EP2 and EP4
prostanoid receptors by prostaglandin E2. Mol Pharmacol. 2005;68(1):251–9.
34. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer.
Cell. 2010;140:883–99.
35. Pan MR, Hou MF, Chang HC, Hung WC. Cyclooxygenase-2 up-regulates
CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic
invasion of breast cancer cells. J Biol Chem. 2008;283:11155–6.
36. Zhang Y, Daaka Y. PGE2 promotes angiogenesis through EP4 and PKA Cγ
pathway. Blood. 2011;118(19):5355–64.
37. Majumder M, Landman E, Liu L, Hess D, Lala PK. COX-2 Elevates Oncogenic
miR-526b in Breast Cancer by EP4 Activation. Mol Cancer Res. 2015;13:1022.
doi:10.1158/1541-7786.MCR-14-0543.
38. Majumder M, Xin X, Liu L, Tutunea-Fatan E, Rodriguez-Torres M, Vincent K,
et al. COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/
WNT Axis. Stem Cells. 2016;34:2290–305.
39. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;35:1709–11.
40. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the
seduction of common sense. JAMA. 2006;296:1653–6.
41. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2
inhibitors and traditional non-steroidal anti-inflammatory drugs increase
the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ.
2006;332:1302–8.
42. Guo Y, Tukaye DN, Wu WJ, et al. The COX-2/PGI2 receptor axis plays an
obligatory role in mediating the cardioprotection conferred by the late
phase of ischemic preconditioning. PLoS One. 2012;7, e41178. doi:10.1371/
journal.pone.0041178.
43. Holt D, Ma X, Kundu N, Fulton A. Prostaglandin E2 (PGE2) suppresses
Natural Killer cell function primarily through the PGE2 receptor EP4. Cancer
Immunol Immunother. 2011;60(11):1577–86.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Nandi et al. BMC Cancer  (2017) 17:11 Page 17 of 17
